Residency · Residency · Preventive Medicine
Tuberculosis Elimination Strategies in Low-Incidence Settings
Overview
Tuberculosis (TB) remains a leading infectious cause of death globally (~1.3 million deaths/year among HIV-negative individuals) The U.S. is a low-incidence setting (~3.0 cases per 100,000 population) but TB elimination (<1 case per million) has been elusive. An estimated 13 million people in the U.S. have latent TB infection (LTBI) -- the reservoir for future active TB. TB in the U.S. disproportionately affects foreign-born individuals (~72% of cases), racial/ethnic minorities, homeless individuals, incarcerated persons, and immunocompromised patients. Elimination strategy requires targeted testing and treatment of LTBI, rapid diagnosis and treatment of active TB, and addressing social determinants.
TB Pathogenesis and Natural History
Caused by Mycobacterium tuberculosis (MTB), an acid-fast bacillus. Transmitted via respiratory droplets (airborne transmission) After exposure: ~70% clear the organism or remain uninfected. ~30% develop LTBI (positive test, no symptoms, not infectious) ~5-10% of LTBI cases progress to active TB over a lifetime (50% within first 2 years) Risk factors for progression from LTBI to active TB: HIV infection (greatest risk factor), immunosuppression (TNF-alpha inhibitors, organ transplant), diabetes, silicosis, malnutrition, recent infection (<2 years), very young or very old age.
Diagnostic Testing
Tuberculin Skin Test (TST)
Intradermal injection of purified protein derivative (PPD), read at 48-72 hours. Measures delayed-type hypersensitivity (cell-mediated immunity) Interpretation thresholds: >= 5 mm: HIV-positive, recent contacts, immunosuppressed, CXR consistent with prior TB. >= 10 mm: foreign-born from high-prevalence countries, IVDU, residents/employees of high-risk settings, children <4, healthcare workers. >= 15 mm: all others (no risk factors) Limitations: false positives from BCG vaccination and NTM exposure; false negatives with anergy, immunosuppression. Two-step testing: used for baseline in serial testing programs (boosting phenomenon)
Interferon-Gamma Release Assays (IGRAs)
Blood tests measuring IFN-gamma release by T cells in response to MTB-specific antigens (ESAT-6, CFP-10) Two FDA-approved: QuantiFERON-TB Gold Plus, T-SPOT.TB. Advantages over TST: single visit, not affected by BCG vaccination, more specific. Preferred for BCG-vaccinated individuals, those unlikely to return for TST reading. Limitations: cannot distinguish LTBI from active TB; limited data in immunocompromised and children <2.
Molecular Diagnostics for Active TB
GeneXpert MTB/RIF (Xpert): rapid PCR-based test detecting MTB and rifampin resistance in <2 hours from sputum. Xpert MTB/RIF Ultra: improved sensitivity, especially in HIV-positive and paucibacillary disease. Sputum AFB smear and culture remain essential (culture is gold standard; takes 2-6 weeks) Drug susceptibility testing (DST): phenotypic and molecular methods for first- and second-line drugs. Whole-genome sequencing: increasingly used for resistance prediction and transmission analysis.
Targeted Testing and Treatment of LTBI
Who to Test (test only those you intend to treat)
Close contacts of active TB cases. Foreign-born from high-prevalence countries (>20 cases/100,000) Residents and employees of high-risk congregate settings (shelters, correctional facilities, long-term care) Healthcare workers with potential exposure. Immunocompromised individuals: HIV, TNF-alpha inhibitor candidates, organ transplant, end-stage renal disease. Persons with CXR findings consistent with prior TB. Children exposed to high-risk adults.
LTBI Treatment Regimens
3HP: isoniazid + rifapentine weekly x 12 weeks (directly observed or self-administered) -- preferred short-course regimen. 4R: rifampin daily x 4 months -- preferred for contacts of isoniazid-resistant TB. 3HR: isoniazid + rifampin daily x 3 months. 6H or 9H: isoniazid daily x 6 or 9 months (traditional regimens; longer courses with lower completion rates) Short-course regimens (3HP, 4R) have comparable efficacy and much higher completion rates than 9H. Monitor for hepatotoxicity: baseline LFTs for those with risk factors; monthly symptom checks for all.
| LTBI Regimen | Drugs | Duration | Frequency | Completion Rate | Key Consideration |
|---|---|---|---|---|---|
| 3HP | Isoniazid + rifapentine | 12 weeks | Weekly (DOT or SAT) | ~80-90% | Preferred short-course; drug interactions with ARVs |
| 4R | Rifampin | 4 months | Daily | ~78% | Preferred for INH-resistant contacts; drug interactions |
| 3HR | Isoniazid + rifampin | 3 months | Daily | ~75% | Alternative short course |
| 9H | Isoniazid | 9 months | Daily | ~50-60% | Traditional; lower completion rate |
| 6H | Isoniazid | 6 months | Daily | ~55% | Acceptable alternative to 9H |
| TST Induration Threshold | Population |
|---|---|
| ≥5 mm | HIV+, recent TB contacts, immunosuppressed, CXR with old TB |
| ≥10 mm | Foreign-born (high-prevalence), IVDU, high-risk settings, HCW, children <4, diabetes |
| ≥15 mm | All others (no risk factors) |
Window Prophylaxis
Contacts of active TB cases who initially test negative may be in the "window period". Start treatment (especially for children <5 and immunocompromised) pending repeat testing at 8-10 weeks post-exposure. If repeat test is negative and exposure has ended, treatment can be discontinued.
Active TB: Diagnosis and Treatment
Clinical Presentation
Pulmonary TB (most common): chronic cough (>2-3 weeks), hemoptysis, night sweats, weight loss, fever. Extrapulmonary TB: lymph nodes, pleura, bone/joint, meninges, genitourinary, peritoneum, miliary (disseminated) CXR findings: upper lobe infiltrates, cavitation (reactivation); hilar lymphadenopathy, middle/lower lobe infiltrates (primary)
Standard Treatment (Drug-Susceptible TB)
Intensive phase: 2 months of isoniazid (INH) + rifampin (RIF) + pyrazinamide (PZA) + ethambutol (EMB) -- RIPE. Continuation phase: 4 months of INH + RIF. Total: 6 months (longer for certain extrapulmonary TB, cavitary disease with delayed culture conversion) Directly Observed Therapy (DOT): standard of care to ensure adherence and prevent resistance. Video DOT (vDOT): remote observation via smartphone -- increasingly accepted.
Drug-Resistant TB Treatment
INH-resistant: modify regimen; use RIF-based backbone. MDR-TB (INH + RIF resistant): 9-18 month regimens; bedaquiline, pretomanid, linezolid-based (BPaL) XDR-TB: limited options; individualized regimens; newer agents (bedaquiline, delamanid, pretomanid) Consultation with TB experts essential for all resistant cases.
Contact Investigation
Cornerstone of TB control in low-incidence settings. Concentric circles approach: start with closest contacts, expand outward based on findings. Prioritize household contacts, workplace/school contacts, social contacts. Evaluate contacts for symptoms, perform TST/IGRA, CXR if positive. Children <5 and immunocompromised contacts receive window prophylaxis. Genomic epidemiology (WGS) can confirm transmission links.
TB in Special Populations
Foreign-Born Individuals
Represent ~72% of U.S. TB cases. Most cases result from reactivation of LTBI acquired before immigration. Overseas screening (immigration medical exam): CXR and sputum testing for those with abnormal CXR. Post-arrival screening and LTBI treatment are critical for elimination. Cultural and linguistic barriers to care must be addressed.
Homeless Individuals
High rates of LTBI and active TB due to congregate living, substance use, immunocompromise. Challenges: unstable housing complicates DOT and follow-up. Innovative approaches: shelter-based screening, respite care for homeless TB patients, incentives for treatment adherence.
HIV-TB Coinfection
HIV is the strongest risk factor for LTBI reactivation. All HIV-positive individuals should be tested for LTBI. Drug interactions between rifamycins and antiretrovirals require careful regimen selection. Immune reconstitution inflammatory syndrome (IRIS) can occur when ART is initiated in TB patients. ART should generally be started within 2 weeks of TB treatment initiation (except in TB meningitis)
<image>A diagram showing the natural history of TB infection and the points of intervention. Starting with exposure to M. tuberculosis, the diagram branches into: no infection (majority), LTBI (30%, positive test, no symptoms, non-infectious), and active TB (5-10% lifetime risk from LTBI). Intervention points are marked: contact investigation after exposure, LTBI testing and treatment to prevent progression, and active TB diagnosis and treatment. Risk factors for progression (HIV, immunosuppression, diabetes, recent infection) are listed at the LTBI-to-active TB transition. TB elimination strategy education illustration.</image>
<image>A comparison table formatted as an infographic showing LTBI treatment regimens: 3HP (12 weekly doses of INH + rifapentine), 4R (daily rifampin x 4 months), 3HR (daily INH + rifampin x 3 months), and 9H (daily INH x 9 months). For each regimen, columns show duration, dosing frequency, completion rates, and key considerations (drug interactions, hepatotoxicity monitoring). Short-course regimens are highlighted as preferred. TB treatment education illustration.</image>
Clinical Pearls
In low-incidence settings, the path to TB elimination runs through LTBI treatment -- there are 500 people with LTBI for every active TB case in the U.S. Short-course LTBI regimens (3HP, 4R) are now preferred because they achieve equivalent protection with much higher completion rates than 9 months of isoniazid. Test only those you intend to treat -- routine LTBI testing in low-risk populations leads to false positives and unnecessary treatment. IGRAs are preferred over TST in BCG-vaccinated individuals because they are not affected by prior BCG vaccination. Congenital syphilis and congenital TB share a common risk factor: inadequate prenatal care. For boards: know the TST induration thresholds, the LTBI treatment regimens, the RIPE regimen for active TB, and the risk factors for LTBI reactivation.
References
- CDC. Guidelines for the Treatment of Latent Tuberculosis Infection. MMWR. 2020;69(1):1-11.
- Nahid P, et al. Official ATS/CDC/IDSA Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
- Sterling TR, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166.
- WHO. Global Tuberculosis Report 2023. WHO; 2023.
- Lewinsohn DM, et al. Official ATS/IDSA/CDC Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):e1-e33.
